Mabion SA (PL:MAB)
:MAB
Top Page
Mabion SA
(MAB)
Select Model
Select Model
Rating:52Neutral
Price Target:
zł8.50
▲(3.16% Upside)
Action:N/ADate:09/14/25
Mabion SA's overall stock score of 52 reflects a cautious outlook, driven primarily by mixed financial performance with significant revenue declines and negative profitability, despite a strong balance sheet and improving cash flows. Valuation concerns due to a negative P/E ratio further weigh on the score, while limited technical data provides no clear bullish or bearish signal. Investors should focus on monitoring revenue recovery and profitability trends.
Positive Factors
Operational Efficiency
Maintaining a positive EBITDA margin indicates operational efficiency, allowing the company to cover its operating expenses and potentially improve profitability over time.
Negative Factors
Declining Gross Profit Margin
A declining gross profit margin indicates rising costs or pricing pressures, which could erode profitability and limit resources available for growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Operational Efficiency
Maintaining a positive EBITDA margin indicates operational efficiency, allowing the company to cover its operating expenses and potentially improve profitability over time.
Read all positive factors
Mabion SA (MAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
zł136.57M
Dividend YieldN/A
Average Volume (3M)38.65K
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue Growth-74.16%
EPS Growth-192.42%
CountryPL
Employees206
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding16,162,327
10 Day Avg. Volume25,807
30 Day Avg. Volume38,648
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.29
Price to Sales (P/S)2.08
P/FCF Ratio5.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.36
Revenue Forecast (FY)zł60.00M
Mabion SA Business Overview & Revenue Model
Company Description
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic...
How the Company Makes Money
Mabion generates revenue primarily through the development and commercialization of its biopharmaceutical products. The company earns money by selling its biosimilars to healthcare providers and pharmaceutical companies, often under licensing agre...
Mabion SA Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
75
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.81M | 69.02M | 151.68M | 163.98M | 56.87M | 0.00 |
| Gross Profit | -26.45M | 41.15M | 114.58M | 65.99M | 28.18M | -9.83M |
| EBITDA | -45.33M | 10.20M | 58.31M | 29.63M | 118.00K | -44.27M |
| Net Income | -59.30M | -6.33M | 41.27M | 23.19M | 1.90M | -57.19M |
Balance Sheet | ||||||
| Total Assets | 120.46M | 159.47M | 208.25M | 186.18M | 184.24M | 78.32M |
| Cash, Cash Equivalents and Short-Term Investments | 4.61M | 38.45M | 47.82M | 53.64M | 48.71M | 2.40M |
| Total Debt | 3.97M | 4.61M | 35.83M | 7.28M | 20.36M | 36.68M |
| Total Liabilities | 50.44M | 48.03M | 90.48M | 109.67M | 130.92M | 155.71M |
| Stockholders Equity | 70.02M | 111.44M | 117.78M | 76.51M | 53.31M | -77.39M |
Cash Flow | ||||||
| Free Cash Flow | -41.46M | 26.28M | -40.33M | 22.11M | -64.53M | -38.60M |
| Operating Cash Flow | -40.50M | 39.86M | -2.33M | 38.84M | -32.91M | -35.24M |
| Investing Cash Flow | -783.00K | -12.29M | -37.98M | -16.06M | -31.28M | -3.00M |
| Financing Cash Flow | -1.16M | -36.95M | 34.49M | -17.84M | 110.50M | 12.67M |
Mabion SA Technical Analysis
Neutral
8.24
Price Trends
8.44
Positive
8.01
Positive
8.50
Positive
Market Momentum
0.08
Positive
46.88
Neutral
11.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:MAB, the sentiment is Neutral. The current price of 8.24 is below the 20-day moving average (MA) of 8.89, below the 50-day MA of 8.44, and below the 200-day MA of 8.50, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 46.88 is Neutral, neither overbought nor oversold. The STOCH value of 11.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PL:MAB.
Mabion SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | zł136.57M | -3.23 | -59.73% | ― | -74.16% | -192.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | zł544.48M | -6.19 | -110.42% | ― | 15.45% | -25.81% | |
42 Neutral | zł448.71M | -4.87 | -109.96% | ― | -40.45% | 27.53% |
* Healthcare Sector Average
PL:MAB
Mabion SA
8.45
-0.70
-7.65%
PL:RVU
Ryvu Therapeutics SA
23.55
-0.95
-3.88%
PL:SCP
Scope Fluidics SA
137.80
-45.20
-24.70%
PL:SVE
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
3.64
-0.74
-16.82%
PL:CTX
Captor Therapeutics SA
80.80
48.80
152.50%
PL:MOC
OncoArendi Therapeutics SA
5.45
-2.60
-32.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.